What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the CheckMate 649 trial demonstrates that nivolumab plus platinum- and fluoropyrimidine-based chemotherapy significantly improves both progression-free survival and overall survival compared to chemotherapy alone, with hazard ratios of 0.70 for both outcomes. This indicates a clear clinical advantage over standard care.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nivolumab are reported to be within acceptable thresholds, with ICERs comfortably below £50,000 per QALY gained in the most plausible scenarios. This indicates that the treatment is marginally cost-effective.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document highlights the significant impact of gastric cancer on quality of life, it does not provide specific HRQoL data from validated instruments. However, the potential for improved survival and the reduction of distressing symptoms suggest a moderate benefit in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of nivolumab is described as acceptable, with manageable adverse events. The document indicates that adverse effects are mostly mild to moderate, supporting a very good tolerability rating.
Was the drug compared against what payers expect? — Comparator Selection
Nivolumab was compared against appropriate standard-of-care treatments (XELOX and FOLFOX), which are the most relevant comparators for this patient population. This ideal head-to-head comparison strengthens the evidence base.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is generally representative of the intended patient population, although there are some concerns regarding age and fitness levels. However, the core population is adequately covered, supporting a moderate rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab can be integrated into existing treatment pathways with manageable adjustments, as it is used in combination with standard chemotherapy regimens. This indicates a good fit with current clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model suggests that the budget impact is manageable and aligns with Healthcare planning, indicating that the resource use is justifiable given the treatment’s benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a robust Phase III RCT (CheckMate 649) with a large sample size and mature data, which supports the credibility and reliability of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the treatment shows promise, there are significant uncertainties regarding long-term survival and treatment effect waning, which could impact decision-making. This leads to a moderate risk rating.
